|
Orthologous residues
|
|
eEF2K (human): S377‑p, eEF2K (mouse): S376‑p, eEF2K (rat): S376‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mass spectrometry, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
HeLa (cervical)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
MAPKAPK2 (human)
|
pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
TNF
|
|
|
|
increase
|
|
|
SB203580
|
TNF
|
|
|
inhibit treatment-induced increase
|
|
|
anisomycin
|
|
|
|
increase
|
|
|
SB203580
|
anisomycin
|
|
|
inhibit treatment-induced increase
|
|
|